Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low vs High Dose OnabotulinumtoxinA for Chronic Anal Fissure
NCT07543315Phase 3Completed
- Sponsor
- Tanta University
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of botulinum toxin type A in chronic anal fissure (CAF), sponsored by Tanta University. Started Aug 2023; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
chronic anal fissure (CAF)
Beyond the preview
Go deeper on NCT07543315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07543315.